GENE ONLINE|News &
Opinion
Blog

2019-12-30| Technology

‘CRISPR Babies’ Researchers Given Prison Sentence by Chinese Court

by Rajaneesh K. Gopinath
Share To

By Rajaneesh K. Gopinath, Ph.D.

In November 2018, Chinese biophysicist He Jiankui shocked the world by announcing his creation of the “CRISPR babies” at an International Summit causing much furor across the globe. The researchers claimed that the intention of the study was to immunize the twin baby sisters Lulu and Nana against HIV by modifying the CCR5 gene in the embryo. However, a recent examination of the unpublished manuscripts by the MIT Technology Review involving four experts have found that the claims made by He and his team are not supported by data.

According to a report from Xinhua news agency, on December 30th, the Shenzhen Nanshan District People’s Court in South China has punished He and his coworkers Zhang Renli and Qin Jinzhou. The defendants were found to be guilty of jointly carrying out human embryo gene editing and reproductive medical activities for reproductive purposes. The court has found that the trio conspired since 2016 and has deliberately violated scientific regulations and crossed ethical boundaries.

While He Jiankui is sentenced to a three-year prison sentence including a fine of 3 million Chinese yuan (US$430,000), the others are given lesser sentences. Zhang Renli was sentenced to two years with a 1 million yuan fine and Qin Jinzhou received an 18-month sentence with a 500,000 yuan fine. All defendants pleaded guilty to the offense.

 

References
  1. https://mp.weixin.qq.com/s/5utIos-cXONVUh7Qn0Za9w
  2. https://www.technologyreview.com/s/614764/chinas-crispr-babies-read-exclusive-excerpts-he-jiankui-paper/

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
Fifth HIV Patient Cured After Stem Cell Transplant in Germany
2023-03-01
Moderna, Life Edit To Develop In Vivo Gene Editing Therapies
2023-02-23
R&D
Treating Common Heart Disease with CRISPR-Cas9 Gene Editing
2022-12-27
LATEST
35% Of Better Therapeutics’ Staff to be Cut to Extend the Company’s Runway
2023-03-27
Pharming’s Joenja Racks Up FDA Approval For Rare Primary Immunodeficiency
2023-03-27
Ways to Reduce Carbon Emission in Cement Manufacturing
2023-03-26
Moderna Injects $76 Million To Kickstart Lipid Nanoparticle Delivery Partnership With Generation Bio
2023-03-24
Shining a Light on Oncology with Rakuten Medical Co-CEO Takashi Toraishi
2023-03-23
Incyte’s Zynyz Secures FDA Approval for Treating a Rare and Aggressive Skin Cancer
2023-03-23
Biohaven Licenses TYK2/JAK1 Dual Inhibitor From China’s Highlight In $970 Million Pact
2023-03-23
Scroll to Top